Full Year 2023 Results
![](https://uniphar.euwest01.umbraco.io/media/fhrhkpzc/ipad-2024.png)
FY 2023 Key Stats
€116.0m
EBITDA
5.6%
Organic GP Growth YoY
15.2%
ROCE
18.3c
Adjusted EPS
![](https://uniphar.euwest01.umbraco.io/media/m0cmefh1/gp-2023.png)
Group Highlights
![](https://uniphar.euwest01.umbraco.io/media/3orh2hpz/gp-cagr.png)
€390.0m
2023 GP
![](https://uniphar.euwest01.umbraco.io/media/rcskrkpc/map.png)
Employees
![](https://uniphar.euwest01.umbraco.io/media/aeihllcy/employees.png)
Partnering with 7 of the top 10 pharma companies
![](https://uniphar.euwest01.umbraco.io/media/lljlklrz/highlight-4.png)
and 7 of the top 10 medical device companies
![](https://uniphar.euwest01.umbraco.io/media/znlkvysr/highlight-4.png)